Research Article
Performance and Logistical Challenges of Alternative HIV-1 Virological Monitoring Options in a Clinical Setting of Harare, Zimbabwe
Table 2
Performance of the plasma VFA, DBS VFA, and p24 to identify virological failure using VLref as the reference assay.
| (a) All patients (). |
| | | Number tested | Correctly classified | Misclassified | Undercalled | Overcalled | Sensitivity | Specificity |
| | VFA plasma (CO = 5,000 cp/mL) | 300 | 280 (93.3%) | 20 (6.6%) | 5/20 | 15/20 | 94.5% | 92.7% | | VFA plasma (CO = 1,000 cp/mL) | 300 | 279 (93.0%) | 21 (7%) | 21/21 | 0/21 | 80.1% | 100% | | VFA DBS (CO = 5,000 cp/mL) | 299 | 262 (87.6%) | 37 (12.3%) | 35/37 | 2/37 | 61.9% | 99.0 | | p24 (CO = 5,000 cp/mL) | 301 | 222 (73.5%) | 79 (26.2%) | 42/79 | 37/79 | 54.3% | 82.3% | | p24 (CO = 1,000 cp/mL) | 301 | 216 (71.7%) | 85 (28.2%) | 52/85 | 33/85 | 49.0% | 83.0% |
|
|
| (b) Treated patients (). |
| | | Number tested | Correctly classified | Misclassified | Undercalled | Overcalled | Sensitivity | Specificity |
| | VFA plasma (CO = 5,000 cp/mL) | 200 | 194 (97.0%) | 6 (3.0%) | 3/6 | 3/6 | 72.7% | 98.0% | | VFA plasma (CO = 1,000 cp/mL) | 200 | 191 (95.5%) | 9 (4.5%) | 9/9 | 0/9 | 35.7% | 100% | | VFA DBS (CO = 5,000 cp/mL) | 199 | 189 (95.0%) | 10 (5.0%) | 10/10 | 0/10 | 9.0% | 100% | | p24 (CO = 5,000 cp/mL) | 201 | 166 (82.5%) | 35 (17.5%) | 5/35 | 30/35 | 54.7% | 84.2% | | p24 (CO = 1,000 cp/mL) | 201 | 163 (81.0%) | 48 (19.0%) | 8/38 | 30/38 | 42.8% | 83.9% |
|
|
